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Background
Systemic form of juvenile idiopathic arthritis (JIA) is
regarded as an autoinflammatory disease. Certain genetic
polymorphisms in genes coding inflammatory proteins
have been associated with the disease. On the other hand
mutations of the MEFV gene cause a monogenic autoin-
flammatory disease, Familial Mediterranean Fever (FMF).
In a previous study in adult rheumatoid arthritis 3 out of
the 25 British patients who developed secondary amy-
loidosis had a mutation/polymorphism in the MEFV
gene.
Aim
To analyse whether mutaions in the MEFV gene had an
association with systemic JIA.
Patients and methods
MEFV mutations were screened in a total of 32 systemic
JIA patients. All had been classified as systemic JIA accord-
ing to the Durban JIA criteria. None had disease character-
istics that met the Tel Hashomer criteria for the diagnosis
of FMF.
Results
2 carrier for M694V and two patients who were homozy-
gote for MEFV mutations. Both of these patients were
among the most severe patients in the group. One had an
excellent response to etanercept whereas the other was
resistant to anti-TNF and other conventional treatments
and had only a partial response to thalidomide. Although
the number of severe mutations were increased in this
small group of patients with systemic JIA the difference
with the Turkish population did not reach statistical sig-
nificance, but the disease causing mutation (M694V) was
significantly high in the patients with systemic JIA(p =
0.02).
Conclusion
However, the severe disease course in the aforementioned
patients suggest that MEFV mutations may be a modifying
genetic factor in systemic JIA.
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